Albalawi Nada Saleh, Almohammadi Maram Ati, Albalawi Ahmad Raja
Geriatrics Department, King Fahad Specialist Hospital, Ministry of Health, Tabuk, SAU.
Training Department, Academic Affairs and Training Administration, Ministry of Health, Tabuk, SAU.
Cureus. 2023 Aug 27;15(8):e44191. doi: 10.7759/cureus.44191. eCollection 2023 Aug.
Topical estrogen is effective for treating postmenopausal vaginal atrophy. However, there is a potential risk of estrogen-related adverse effects. There is a need for finding effective non-hormonal treatment for vaginal atrophy. The topical application of moisturising agents, such as hyaluronic acid (HA), represents a promising non-hormonal treatment for the relief of vaginal atrophy. This study aimed to summarize the evidence regarding the efficacy of topical HA compared to topical estrogen in postmenopausal women with vaginal atrophy. The literature search covered English-published studies from database inception till February 2023. The search included the electronic databases of MEDLINE/PubMed, Cochrane Library, Web of Science, ProQuest, and Scopus, using the terms "Hyaluronic Acid" AND "Postmenopause" AND "Vagina" AND "Atrophy". Due to the diversity in reporting outcomes, meta-analysis was not feasible. A narrative synthesis with a systematic approach was conducted by vote counting of studies that included a direct comparison between topical HA and topical estrogen. Six studies were included. Intra-group comparisons showed that both interventions were significantly effective in alleviating the symptoms of vaginal atrophy and dyspareunia as well as improving vaginal pH and cell maturation index. However, inter-group comparisons in most studies showed that estrogen was superior to HA in relieving vaginal symptoms and improving vaginal pH, dyspareunia, and the cell maturation index. There is no evidence to show the superiority of HA to estrogen in the treatment of postmenopausal vaginal atrophy. However, the therapeutic efficacy of HA seems to be comparable to estrogen and considering its safety, HA can be used as an alternative to estrogen in patients who do not want to use estrogen. The available studies have several limitations, and the reporting of outcomes was considerably heterogeneous.
局部用雌激素对治疗绝经后阴道萎缩有效。然而,存在雌激素相关不良反应的潜在风险。需要找到治疗阴道萎缩的有效非激素疗法。局部应用保湿剂,如透明质酸(HA),是一种有前景的缓解阴道萎缩的非激素疗法。本研究旨在总结与局部用透明质酸相比局部用雌激素治疗绝经后阴道萎缩女性疗效的相关证据。文献检索涵盖从数据库建立至2023年2月发表的英文研究。检索包括MEDLINE/PubMed、Cochrane图书馆、科学网、ProQuest和Scopus的电子数据库,使用检索词“透明质酸”、“绝经后”、“阴道”和“萎缩”。由于报告结果的多样性,荟萃分析不可行。通过对纳入局部用透明质酸和局部用雌激素直接比较的研究进行投票计数,采用系统方法进行叙述性综合分析。纳入了六项研究。组内比较显示,两种干预措施在缓解阴道萎缩和性交困难症状以及改善阴道pH值和细胞成熟指数方面均显著有效。然而,大多数研究的组间比较显示,雌激素在缓解阴道症状、改善阴道pH值、性交困难和细胞成熟指数方面优于透明质酸。没有证据表明透明质酸在治疗绝经后阴道萎缩方面优于雌激素。然而,透明质酸的治疗效果似乎与雌激素相当,考虑到其安全性,对于不想使用雌激素的患者,透明质酸可作为雌激素的替代品。现有研究存在若干局限性,且结果报告存在很大异质性。